Investigator Sponsored Research

Due to the ongoing Coronavirus (COVID-19) pandemic, we ask for your patience regarding possible delays in the processing of new grant requests. The Global Medical Grants (GMG) team is currently providing grantees of current/ongoing studies and initiatives with information to ensure the health and safety of all involved in Pfizer-supported activities.

Pfizer supports Investigator Sponsored Research (ISR) projects that advance medical and scientific knowledge about our therapies.

An ISR is a type of grant that supports an independent research study where the investigator or organization is the sponsor of the study and where Pfizer provides financial and/or non-financial support for the development or refinement of specific and defined medical knowledge relating to a Pfizer asset. This global program is open to all researchers who are interested in conducting their own research. This grant type is used as support for pre-clinical and clinical studies (including interventional and non-interventional), that involve a Pfizer asset (e.g., commercial drug, investigational drug, pure compound*).

*Pfizer has an extensive pure substance library that encompasses our publicly known compounds.

General Research

Pfizer also supports general research projects focused on the development or refinement of specific and defined medical knowledge unrelated to a Pfizer asset.

This grant type is used to support research that does not include the study of a Pfizer asset, including health services research unrelated to a Pfizer asset, registry development and/or queries unrelated to a Pfizer asset, and outcomes research unrelated to a Pfizer asset. This includes observational studies, such as epidemiology studies and certain outcomes research studies where the primary focus is the scientific understanding of disease as well as other types of independent research on disease states.

If you would like to view the Research Grant application prior to submission please click here

If you have any additional questions please email us at [email protected].